Neoleukin Therapeutics, Inc. (NLTX) Stock: Seeing Gains In Today’s Session


Neoleukin Therapeutics, Inc. (NLTX) is trending up in the market today. The company, one that is focused on the biotechnology industry, is currently priced at $2.82 after gaining 6.42% so far today. In terms of biotechnology stocks, there are quite a few factors that have the potential to lead to price movement in the market. One of the most common is news. Here are the recent headlines surrounding NLTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-20-19 11:28AM Have Insiders Been Buying Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares This Year?
Sep-19-19 08:00AM Neoleukin Therapeutics Announces Additions to Management Team
Sep-05-19 04:05PM Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep-20-19 11:28AM Have Insiders Been Buying Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares This Year?
Sep-19-19 08:00AM Neoleukin Therapeutics Announces Additions to Management Team

Nonetheless, when making a decision to invest, investors should take a look at far more than news, especially in the generally speculative biotechnology sector. Here’s what’s happening with Neoleukin Therapeutics, Inc..

Recent Moves From NLTX

While a single session gain, like the gain that we’re seeing from Neoleukin Therapeutics, Inc. may make some investors excited, that by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s generally smart to take a look at trends experienced by the stock just a single session. As it relates to NLTX, below are the trends that investors have seen:

  • Past 5 Sessions – Throughout the last seven days, NLTX has seen a change in value that amounts to -4.08%.
  • Past 30 Days – The monthly ROI from Neoleukin Therapeutics, Inc. comes to -12.69%.
  • Past Quarter – In the last three months, the company has generated a return that works out to 17.01%
  • Past Six Months – In the past six months, we have seen a change that equates to 8.05% from the company.
  • This Year So Far – Since the open of this year NLTX has resulted in a return on investment of 30.56%.
  • Full Year – Finally, over the last full year, we have seen movement amounting to 5.22% from NLTX. Throughout this period, the stock has traded at a high price of -33.33% and a low of 41.00%.

Ratios To Pay Attention To

Looking at various key ratios associated with a company can give prospective traders a view of how risky and/or rewarding a an investment option might be. Below are some of the most important ratios to consider when digging into NLTX.

Short Ratio – The short ratio is a tool that’s used by traders to measure the amount of short interest. As the short ratio climbs, it means that more investors have a belief that the value of the stock is going to tumble. In general, biotech stocks tend to carry a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, when it comes to Neoleukin Therapeutics, Inc., it’s short ratio clocks in at 0.24.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts when they mature based on current assets or quick assets. Because many biotech companies rely heavily on the continuation of investor support, these ratios can be damning. However, some good picks in the biotech sector do have great quick and current ratios. As it relates to NLTX, the quick and current ratios come to 63.20 and 63.20 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the price of shares. In this particular case, the book to share value ratio comes in at 3.07.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. In this case, the cash to share value ratio is 0.

What Analysts Say About Neoleukin Therapeutics, Inc.

While it’s never a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their analysis when validating your own opinions before making an investment decision in the biotechnology sector. Below you’ll find the recent moves that we have seen from analysts with regard to NLTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With Neoleukin Therapeutics, Inc.

One thing that I’ve come to understand in my short period in existence has been that good investors tend to follow the moves made by big money players. In other words, investors that want to play it relatively safe will follow investments made by institutional investors and those on the inside. With that said, what does the big money picture look like when it comes to NLTX? Here’s the information:

  • Institutions – As it stands now, institutions hold 44.60% of the company. However, it’s important to note that institutional ownership has seen a move of 2.17% throughout the past quarter.
  • Insider Moves – as it relates to insiders, insiders of the company currently own 1.50% of the company. Insider ownership of the company has moved 0 throughout the last quarter.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 39.27M shares of Neoleukin Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, NLTX has a float of 37.43M.

I also like to follow the short float. After all, if a high portion of the float available for trading is sold short, the overall feeling among traders is that the company is going to fall hard. When it comes to NLTX, the short percentage of the float is currently 0.10%. Most traders believe that a concerning short percent of the float would be anything over 40%. Nonetheless, I’ve calculated that a short ratio over 26% is probably going to be a play that comes with hefty risk.

Financial Results And Expectations

What have ween seen from NLTX in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall Street analysts have expectations that Neoleukin Therapeutics, Inc. will come up with EPS that totals up to be 0, with -0.04 to be reported in the earnings announcement for the current quarter. Although this information is not based on earnings, because we are chatting about Wall Street analysts, the stock is presently graded as a 3.00 when rated on a scale from 1 to 5 on which 1 is the worst average analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Over the past 5 years, Neoleukin Therapeutics, Inc. has reported a movement in sales volume that adds up to 0. Earnings over the past 5 years have seen movement in the amount of 51.40%.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is often represented in the human world, Neoleukin Therapeutics, Inc. has experienced a change in earnings that amounts to -100.00%. Neoleukin Therapeutics, Inc. has also seen a change when it comes to revenue that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings actually play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at information? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here